Checkpoint Therapeutics Stock
Your prediction
Pros and Cons of Checkpoint Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Checkpoint Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Checkpoint Therapeutics | - | - | - | - | - | - | - |
| Heron Therapeutics Inc. | -0.220% | -3.745% | -32.094% | -64.610% | -37.702% | -50.322% | -95.078% |
| Evolus Inc | -6.990% | -4.945% | -5.978% | -68.829% | -36.514% | -55.065% | -67.664% |
| Sangamo Therapeutics Inc. | 18.000% | -12.659% | -29.343% | -56.626% | -25.243% | -83.840% | -97.492% |
Comments
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $4.80 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat
Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) is now covered by analysts at D. Boral Capital. They set a "buy" rating and a $9.00 price target on the stock.
Show more
Ratings data for CKPT provided by MarketBeat